Affordable Access

Publisher Website

Antifungals: what's in the pipeline

Authors
Journal
Current Opinion in Microbiology
1369-5274
Publisher
Elsevier
Publication Date
Volume
4
Issue
5
Identifiers
DOI: 10.1016/s1369-5274(00)00248-4
Keywords
  • Antimicrobials
Disciplines
  • Medicine

Abstract

Abstract The therapeutic landscape for mycotic infections is shifting. New generation azoles that are active against clinically relevant, drug-resistant fungal pathogens have improved bioavailability, half-lives and safety profiles. Acylated cyclic peptide inhibitors of β(1,3)glucan synthesis with origins as fungal metabolites provide an alternative and highly-selective mode of action, targeting cell-wall biogenesis in important pathogens such as Candida and Aspergillus species. The development, in each structural class, of compounds that have advanced to late-stage clinical trials is summarized in this review.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Antifungals: what's in the pipeline.

on Current Opinion in Microbiolog... October 2001

What's in the pipeline?

on American pharmacy September 1995

What's in the pipeline.

on Behavioral healthcare December 2007
More articles like this..